Latest Compliance News

Percheron Therapeutics has raised $2.3 million through an institutional placement to fully fund its upcoming acute myeloid leukemia clinical trial led by Vanderbilt Health.

CurveBeam AI has secured over A$600,000 through its Share Purchase Plan, bolstering funds alongside a recent A$5 million placement. The capital will fuel the China launch and product development for its HiRise™ CT scanner.

Identitii has issued nearly 200,000 shares to partially repay a $395,000 loan, reducing its debt by $128,944 through a debt-to-equity swap.

Volt Group (ASX: VPR) is set to repurchase up to 5% of its shares over 12 months starting 16 September 2026, aiming to optimise capital structure without requiring shareholder approval.

Capstone Copper has boosted its Atacama presence by acquiring the San Pietro copper project, adding 16,000 hectares and nearly half a billion tonnes of inferred resources to its Mantoverde-Santo Domingo district.

Sparc Technologies has made its inaugural commercial delivery of ecosparc®, a graphene additive, to a major coatings manufacturer, underpinning its push to dominate the protective coatings market. The company also launched a discounted Share Purchase Plan to fuel ongoing commercial expansion.

Collins Foods posted record FY26 revenue and underlying profit, exited Taco Bell to focus on KFC growth, and outlined ambitious expansion plans in Germany and Australia.

RMA Global grew revenue 7% to $22.7 million in FY26, driven by US market gains and integration of Curated Social, but losses widened to $3.5 million. The company rebranded as Renowned and secured record US brokerage deals.

Osteopore Limited’s half-year results show an 8% revenue drop driven by currency effects, while losses widen 14% as the company invests heavily in product development and market growth.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.

Salter Brothers Emerging Companies Limited (ASX:SB2) swung to a $7.9 million loss for FY26, driven by a $10.5 million investment write-down, while maintaining dividend payments and extending its share buy-back program.